The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP

Conclusions
These results indicate that therapeutically relevant concentrations of beraprost can inhibit VSMC migration via a previously unknown mechanism involving the cAMP mediator Epac. This may provide a novel target that could blunt neointimal formation.

Source: Cardiovascular Research - August 18, 2015 Category: Cardiology Authors: McKean, J. S., Murray, F., Gibson, G., Shewan, D. A., Tucker, S. J., Nixon, G. F. Tags: Vascular biology Source Type: research